Cargando…
Two decades (1998 to 2018) of collaborative human immunodeficiency virus clinical pharmacology capacity building in a resource constrained setting
While important advances have been made in the prevention and treatment of Human Immunodeficiency Virus (HIV) infection, limited expertise and resource constraints to effectively manage rollout of HIV programs often contribute to poor treatment outcomes in Sub-Saharan Africa. In 1998, the University...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8579570/ https://www.ncbi.nlm.nih.gov/pubmed/34758831 http://dx.doi.org/10.1186/s12962-021-00327-y |
_version_ | 1784596453113462784 |
---|---|
author | Maponga, Charles C. Monera-Penduka, Tsitsi G. Mtisi, Takudzwa J. Difrancesco, Robin Makita-Chingombe, Faithful Mazambara, Fine Tooley, Kathleen Mudzviti, Tinashe Morse, Gene D. |
author_facet | Maponga, Charles C. Monera-Penduka, Tsitsi G. Mtisi, Takudzwa J. Difrancesco, Robin Makita-Chingombe, Faithful Mazambara, Fine Tooley, Kathleen Mudzviti, Tinashe Morse, Gene D. |
author_sort | Maponga, Charles C. |
collection | PubMed |
description | While important advances have been made in the prevention and treatment of Human Immunodeficiency Virus (HIV) infection, limited expertise and resource constraints to effectively manage rollout of HIV programs often contribute to poor treatment outcomes in Sub-Saharan Africa. In 1998, the University of Zimbabwe (UZ) and the University at Buffalo, State University of New York (UB), developed a collaborative clinical pharmacology capacity building program in Zimbabwe to train the next generation of HIV researchers and support rollout of the national HIV program. The collaboration was funded by research and training grants that were competitively acquired through United States of America government funding mechanisms, between 1998 and 2016. Thirty-eight research fellows were trained and a specialty clinical pharmacology laboratory was established during this period. Knowledge and skills transfer were achieved through faculty and student exchange visits. Scientific dissemination output included sixty-two scholarly publications that influenced three national policies and provided development of guidelines for strategic leadership for an HIV infection—patient adherence support group. The clinical pharmacology capacity building program trained fellows that were subsequently incorporated into the national technical working group at the Ministry of Health and Child Care, who are responsible for optimizing HIV treatment guidelines in Zimbabwe. Despite serious economic challenges, consistent collaboration between UZ and UB strengthened UZ faculty scholarly capacity, retention of HIV clinical research workforce was achieved, and the program made additional contributions toward optimization of antiretroviral therapy in Zimbabwe. |
format | Online Article Text |
id | pubmed-8579570 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-85795702021-11-10 Two decades (1998 to 2018) of collaborative human immunodeficiency virus clinical pharmacology capacity building in a resource constrained setting Maponga, Charles C. Monera-Penduka, Tsitsi G. Mtisi, Takudzwa J. Difrancesco, Robin Makita-Chingombe, Faithful Mazambara, Fine Tooley, Kathleen Mudzviti, Tinashe Morse, Gene D. Cost Eff Resour Alloc Review While important advances have been made in the prevention and treatment of Human Immunodeficiency Virus (HIV) infection, limited expertise and resource constraints to effectively manage rollout of HIV programs often contribute to poor treatment outcomes in Sub-Saharan Africa. In 1998, the University of Zimbabwe (UZ) and the University at Buffalo, State University of New York (UB), developed a collaborative clinical pharmacology capacity building program in Zimbabwe to train the next generation of HIV researchers and support rollout of the national HIV program. The collaboration was funded by research and training grants that were competitively acquired through United States of America government funding mechanisms, between 1998 and 2016. Thirty-eight research fellows were trained and a specialty clinical pharmacology laboratory was established during this period. Knowledge and skills transfer were achieved through faculty and student exchange visits. Scientific dissemination output included sixty-two scholarly publications that influenced three national policies and provided development of guidelines for strategic leadership for an HIV infection—patient adherence support group. The clinical pharmacology capacity building program trained fellows that were subsequently incorporated into the national technical working group at the Ministry of Health and Child Care, who are responsible for optimizing HIV treatment guidelines in Zimbabwe. Despite serious economic challenges, consistent collaboration between UZ and UB strengthened UZ faculty scholarly capacity, retention of HIV clinical research workforce was achieved, and the program made additional contributions toward optimization of antiretroviral therapy in Zimbabwe. BioMed Central 2021-11-10 /pmc/articles/PMC8579570/ /pubmed/34758831 http://dx.doi.org/10.1186/s12962-021-00327-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Maponga, Charles C. Monera-Penduka, Tsitsi G. Mtisi, Takudzwa J. Difrancesco, Robin Makita-Chingombe, Faithful Mazambara, Fine Tooley, Kathleen Mudzviti, Tinashe Morse, Gene D. Two decades (1998 to 2018) of collaborative human immunodeficiency virus clinical pharmacology capacity building in a resource constrained setting |
title | Two decades (1998 to 2018) of collaborative human immunodeficiency virus clinical pharmacology capacity building in a resource constrained setting |
title_full | Two decades (1998 to 2018) of collaborative human immunodeficiency virus clinical pharmacology capacity building in a resource constrained setting |
title_fullStr | Two decades (1998 to 2018) of collaborative human immunodeficiency virus clinical pharmacology capacity building in a resource constrained setting |
title_full_unstemmed | Two decades (1998 to 2018) of collaborative human immunodeficiency virus clinical pharmacology capacity building in a resource constrained setting |
title_short | Two decades (1998 to 2018) of collaborative human immunodeficiency virus clinical pharmacology capacity building in a resource constrained setting |
title_sort | two decades (1998 to 2018) of collaborative human immunodeficiency virus clinical pharmacology capacity building in a resource constrained setting |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8579570/ https://www.ncbi.nlm.nih.gov/pubmed/34758831 http://dx.doi.org/10.1186/s12962-021-00327-y |
work_keys_str_mv | AT mapongacharlesc twodecades1998to2018ofcollaborativehumanimmunodeficiencyvirusclinicalpharmacologycapacitybuildinginaresourceconstrainedsetting AT monerapendukatsitsig twodecades1998to2018ofcollaborativehumanimmunodeficiencyvirusclinicalpharmacologycapacitybuildinginaresourceconstrainedsetting AT mtisitakudzwaj twodecades1998to2018ofcollaborativehumanimmunodeficiencyvirusclinicalpharmacologycapacitybuildinginaresourceconstrainedsetting AT difrancescorobin twodecades1998to2018ofcollaborativehumanimmunodeficiencyvirusclinicalpharmacologycapacitybuildinginaresourceconstrainedsetting AT makitachingombefaithful twodecades1998to2018ofcollaborativehumanimmunodeficiencyvirusclinicalpharmacologycapacitybuildinginaresourceconstrainedsetting AT mazambarafine twodecades1998to2018ofcollaborativehumanimmunodeficiencyvirusclinicalpharmacologycapacitybuildinginaresourceconstrainedsetting AT tooleykathleen twodecades1998to2018ofcollaborativehumanimmunodeficiencyvirusclinicalpharmacologycapacitybuildinginaresourceconstrainedsetting AT mudzvititinashe twodecades1998to2018ofcollaborativehumanimmunodeficiencyvirusclinicalpharmacologycapacitybuildinginaresourceconstrainedsetting AT morsegened twodecades1998to2018ofcollaborativehumanimmunodeficiencyvirusclinicalpharmacologycapacitybuildinginaresourceconstrainedsetting |